AstraZeneca taps two more targets from its AI partner, again in CKD and IPF

AstraZeneca is doubling down in chronic kidney disease and idiopathic pulmonary fibrosis by selecting one target for each of those via its AI-powered partner.

Originally teamed up in 2019, the Big Pharma has now selected a total of five targets via its UK counterpart, BenevolentAI. The tally includes two targets in CKD and three in IPF, a lung-scarring and breathing-constriction disease with two approved drugs — Boehringer Ingelheim’s Ofev and Roche’s Esbriet, both given the nod in 2014 — and a recent generic entry.

The two new targets trigger two milestone payments to the London-based startup, BenevolentAI said Thursday morning. AstraZeneca EVP of BioPharma R&D, Mene Pangalos, said the new targets are “novel rare variants,” in a statement.

The news comes nine months after the pair upped the collaboration with two more disease areas — heart failure and systemic lupus erythematosus — in a three-year extension to…
Click here to view original post